Biohaven Ltd., a New Haven-based bioscience firm, its chief executive officer and its chief financial officer are being sued ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between ...

--Biohaven Ltd., a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common ...

Biohaven acquired BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, as part of a February 2022 buyout of Channel Biosciences, a subsidiary of Knopp Biosciences.

Biohaven reported that its novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, demonstrated encouraging preliminary clinical activity ...

Biohaven's treatment, taldefgrobep alfa, was being tested in patients with spinal muscular atrophy (SMA) — the leading genetic cause of infant deaths globally. It leaves children too weak to ...

Biohaven Pharmaceutical said on Monday its experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late ...

Biohaven's pipeline is broad with multiple late stage molecules. Analysis based on Biohaven's 01/2025 J.P. Morgan Healthcare Conference Highlights and Presentation, Q3 2024 Earnings Release, and 10-Q.

Biohaven Ltd. (NYSE:BHVN) is one of the best low priced pharma stocks to buy now. Earlier on June 10, Bexorg Inc., which is a techbio company focused on central nervous system/CNS disorders ...

Shares of Biohaven Ltd. BHVN climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed the progress of the condition in a clinical trial.

Biohaven Pharmaceutical Holding Company Ltd., parent company of Biohaven Therapeutics, is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to ...

A Biohaven Pharmaceuticals drug developed to treat disease by modulating a neurotransmitter that’s important to normal brain function has failed a pivotal study in a rare neuromuscular disorder ...